Analyzing Amgen's Financials, Opportunities, and Risks: Is It Worth Investing in AMGN Stock Today?
Higher revenue and lower earnings ahead
In 2024, Amgen projects revenue growth but anticipates reduced earnings per share due to acquisition costs. The decline in Enbrel sales and potential patent expiration pose future challenges.
Will its acquisitions pay off for investors?
Amgen's recent acquisitions, including Horizon Therapeutics and ChemoCentryx, aim to boost revenue. However, the growing debt load from acquisitions may limit future growth and earnings.
Investors have been discounting Amgen's stock
The stock's current valuation is attractive, but the high debt load has deterred risk-averse investors. While potential upside exists, caution is advised due to uncertainties about acquisitions and debt management.
Is Amgen stock a buy?
Amgen's reliance on acquisitions and debt raise concerns for long-term investors. While the stock offers value and a dividend yield, a wait-and-see approach is recommended to assess its ability to balance debt, dividends, and growth.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.